Plasma rico en plaquetas en superficie ocular

Riestra, Ana Cristina; Alonso-Herreros, José María; Merayo‐Lloves, Jesús

doi:10.1016/j.oftal.2016.03.001

Cited by 12 publications

(10 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 27 , 32 It is known that the increased activity of TGF-β leads to the increase of deposits in the extracellular matrix of the trabecular tissue, with increase in the outflow resistance of the aqueous humor, and the consequent elevation of intraocular pressure; anti-TGF-β drugs are being developed as possible therapeutic options for glaucoma. 32 , 33 In vitro and in vivo studies have shown that PRGF eye drops can modulate the activity of TGF-β, decreasing tissue fibrosis and favoring cell regeneration, 16 , 15 these mechanisms could explain the decrease in intraocular pressure.…”

Section: Discussionmentioning

confidence: 99%

“…It has a standardized manufacturing protocol; calcium chloride is used as a platelet activator, which initiates a greater release of growth factors, 13 , 14 and when the PRGF is heated at 56°C for 1 hour, the immunoglobulin E content and complement activity are reduced, and its stability can be maintained up to 6 months. 15 All these technical advantages have not been demonstrated by other PRP. Additionally, there is ample evidence of the efficacy and safety of the use of PRGF eye drops in pathologies of the ocular surface and cornea 16 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma

Sánchez-Ávila¹,

Merayo‐Lloves²,

Fernández³

et al. 2018

IMCRJ

View full text Add to dashboard Cite

PurposeTo evaluate the efficacy and safety of plasma rich in growth factors (PRGF) eye drops in patients with glaucoma with secondary ocular surface disorders (OSDs) due to surgeries and topical hypotensive drugs use.Materials and methodsA retrospective case-series study design was used including six patients (eight eyes) diagnosed with glaucoma who received surgical (nonpenetrating deep sclerectomy and/or trabeculectomy) and medical treatments (hypotensive eye drops) to control intraocular pressure (IOP) and who developed secondary OSDs, unresponsive to conventional treatments. Patients were treated with PRGF eye drops (four times a day). Outcome measures were ocular surface disease index (OSDI), best-corrected visual acuity (BCVA, in logarithm of the minimum angle of resolution), visual analog scale (VAS), frequency and severity of symptoms, and IOP. The safety of the treatment was also evaluated.ResultsSix patients (seven eyes with open-angle glaucoma and one eye with uveitic glaucoma) treated with PRGF eye drops were evaluated. Mean age was 71 years (SD=7.2, range 58–79 years). Five were female and one was male. The mean treatment time was 21.8 weeks (SD=9.0, range 12–36 weeks). The mean time to reach closure of the corneal ulcer was 14.5 (SD=5.5) weeks. A statistical significant reduction in OSDI scale (50.6%), VAS frequency (53.1%), VAS severity (42.0%), and a 41.8% improvement in BCVA were observed (p<0.05). IOP also decreased by 16.6% (p=0.010). Only one of the six patients reported itching in both eyes as an adverse event (AE); however, the patient continued with the PRGF eye drops until the end of therapy; the remaining patients did not report any AEs during the follow-up period.ConclusionsIn patients with glaucoma and secondary OSDs refractive to conventional treatments, the treatment with PRGF eye drops could be considered a possible therapeutic option, because it demonstrates an improvement in the signs and symptoms of the ocular surface, as well as a better control of the IOP. This is an initial research work that can open doors for future research to confirm these findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma

Sánchez-Ávila¹,

Merayo‐Lloves²,

Fernández³

et al. 2018

IMCRJ

View full text Add to dashboard Cite

show abstract

“…Currently, there are more than 40 different preparation methods, which makes it difficult to compare different scientific results in terms of both efficacy and safety [ 13 , 35 , 38 ]. Regarding the industrialization of PRGF eye drops, there are studies of preservation and biological activity for 3 months in human use, with good outcomes in the care for patients with severe dry eye that do not respond to conventional therapy [ 39 ], with special success in neutrophic cases [ 40 ].…”

Section: Hemoderivativesmentioning

confidence: 99%

“…The role of non-platelet components of whole blood contributes to their biological activity—in particular, red and white blood cells may be detrimental by participating in unwanted inflammatory reactions. In spite of the possible negative pro-inflammatory effect caused by the presence of leukocyte [ 29 , 38 ], other studies suggest that the non-platelet cellular components are important for optimal platelet function, including thrombin generation leading to robust coagulation, growth factor release, and the resulting capacity of the serum to stimulate cell proliferation [ 36 ].…”

Section: Hemoderivativesmentioning

confidence: 99%

“…Different investigations have evaluated the safety and efficacy of the use of different PRP preparations in the treatment of dry eye, demonstrating an improvement in tear film quality and the severity of symptoms, even in patients previously treated with AS [ 38 , 39 ]. PRP has certain contraindications to its use, such as serious cardiac disease in the extraction phase, active bacterial infections, and a history of certain viral infectious diseases (B hepatitis, HIV, etc.)…”

Section: Hemoderivativesmentioning

confidence: 99%

See 1 more Smart Citation

Regenerative Therapies in Dry Eye Disease: From Growth Factors to Cell Therapy

Villatoro

Fernández

Claros

et al. 2017

IJMS

View full text Add to dashboard Cite

Dry eye syndrome is a complex and insidious pathology with a high level of prevalence among the human population and with a consequently high impact on quality of life and economic cost. Currently, its treatment is symptomatic, mainly based on the control of lubrication and inflammation, with significant limitations. Therefore, the latest research is focused on the development of new biological strategies, with the aim of regenerating affected tissues, or at least restricting the progression of the disease, reducing scar tissue, and maintaining corneal transparency. Therapies range from growth factors and cytokines to the use of different cell sources, in particular mesenchymal stem cells, due to their multipotentiality, trophic, and immunomodulatory properties. We will review the state of the art and the latest advances and results of these promising treatments in this pathology.

show abstract